Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BioCorRx Inc. is a publicly traded healthcare company focused on substance use disorder recovery and related wellness solutions. The company operates primarily in the addiction treatment and recovery services and nutraceutical wellness industries, with offerings designed to support individuals recovering from alcohol and opioid dependence. Its core activities center on non-invasive recovery support products, education, and program-based services marketed to treatment centers, healthcare providers, and directly to consumers.
The company’s primary revenue drivers have historically included branded nutraceutical products and recovery support programs, most notably UnLOC™, a proprietary nutraceutical formula, and the Start Fresh Program, which integrates supplements, educational content, and recovery planning. BioCorRx Inc. was founded in 2008 and initially pursued implant-based treatment concepts for addiction recovery before evolving toward nutraceuticals, digital education, and programmatic support models as regulatory, clinical, and capital constraints shaped its strategy.
Business Operations
BioCorRx Inc. operates as a single-reporting business with activities concentrated in the United States. The company generates revenue through the sale of branded nutraceutical products, licensing or program participation fees from treatment providers, and direct-to-consumer sales channels. Operations are relatively asset-light, relying on third-party manufacturers, distribution partners, and contracted service providers rather than vertically integrated production facilities.
The company has conducted past research and development activities through BioCorRx Pharmaceuticals Inc., a subsidiary formed to pursue pharmaceutical and implant-based treatment technologies. Public disclosures indicate that these activities have been scaled back, restructured, or deprioritized over time. Data inconclusive based on available public sources regarding any active joint ventures or material long-term strategic partnerships currently contributing significant revenue.
Strategic Position & Investments
Strategically, BioCorRx Inc. positions itself as a complementary provider within the addiction recovery ecosystem rather than a primary clinical treatment provider. Growth initiatives have emphasized expanding awareness and adoption of UnLOC™, enhancing digital and educational recovery content, and pursuing distribution relationships with rehabilitation centers and wellness providers. The company has periodically stated an intent to align with emerging behavioral health trends, including holistic and non-pharmaceutical recovery support.
The company has completed limited acquisitions historically, primarily focused on intellectual property or product rights rather than large-scale corporate transactions. No material controlling investments in unrelated portfolio companies have been verified in recent public filings. While management has referenced interest in emerging healthcare technologies, including digital health tools, Data inconclusive based on available public sources regarding material investments or commercially deployed platforms in these areas.
Geographic Footprint
BioCorRx Inc. is headquartered in Southern California, United States, and its operational and commercial activities are predominantly domestic. Sales, marketing, and program partnerships are primarily focused on the United States healthcare and wellness markets, particularly regions with higher concentrations of addiction treatment facilities.
International operations and foreign revenue contributions have not been identified as material in recent public disclosures. While products may be accessible online, Data inconclusive based on available public sources regarding any sustained international distribution networks, subsidiaries, or regulatory approvals outside the United States.
Leadership & Governance
BioCorRx Inc. was founded by Brady Granier, who has played a central role in shaping the company’s recovery-focused mission. Leadership has emphasized personal accountability, long-term recovery support, and the integration of wellness-based solutions alongside traditional treatment approaches. Governance follows a standard public-company structure with a board of directors overseeing strategic and financial reporting obligations.
Key executives include:
- Brady Granier – Chief Executive Officer
- Brady Granier – Founder
- Mark Davis – Chief Financial Officer (title and tenure reported in public filings; responsibilities include financial reporting and compliance)
- Additional executive or senior management roles – Data inconclusive based on available public sources regarding long-term appointments beyond those disclosed in recent filings
Leadership communications consistently highlight a strategic vision centered on expanding access to recovery support tools while maintaining regulatory compliance and financial discipline appropriate for a small-cap public healthcare company.